TG Therapeutics, Inc. (MHA) Announces Presentation of Interim Results From Its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients With Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma
6/3/2013 9:06:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin's Lymphoma (NHL), presented at the American Society of Clinical Oncology Meeting on June 2, 2013. The poster presentation, entitled "A Phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients," was presented by Principal Investigator, Dr. Owen A. O'Connor of Columbia University (Abstract #8575). The poster is available on the Company's website (www.tgtherapeutics.com) under the quick links section entitled "Publications."
Help employers find you! Check out all the jobs and post your resume.
comments powered by